Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.

Leung DH, Wirth S, Yao BB, Viani RM, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Narkewicz MR, Sokal E, Fortuny C, Hsu EK, Del Valle-Segarra A, Zha J, Larsen L, Liu L, Shuster DL, Cohen DE, Rosenthal P.

Hepatol Commun. 2018 Oct 5;2(11):1311-1319. doi: 10.1002/hep4.1250. eCollection 2018 Nov.

2.

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.

Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K.

Lancet Gastroenterol Hepatol. 2019 Jan;4(1):45-51. doi: 10.1016/S2468-1253(18)30341-8. Epub 2018 Nov 2.

PMID:
30393106
3.

Shared genetic etiology of hypertension and stroke: evidence from bioinformatics analysis of genome-wide association studies.

Ji LD, Hu SP, Li JY, Yao BB, Shen QJ, Xu J.

J Hum Hypertens. 2017 Dec;32(1):34-39. doi: 10.1038/s41371-017-0012-3. Epub 2017 Nov 24.

PMID:
29176593
4.

Are genetic polymorphisms in the renin-angiotensin-aldosterone system associated with essential hypertension? Evidence from genome-wide association studies.

Ji LD, Li JY, Yao BB, Cai XB, Shen QJ, Xu J.

J Hum Hypertens. 2017 Nov;31(11):695-698. doi: 10.1038/jhh.2017.29. Epub 2017 Apr 20. Review.

PMID:
28425437
5.

Protective effects of traditional Tibetan medicine Zuo-Mu-A Decoction () on the blood parameters and myocardium of high altitude polycythemia model rats.

Lu MQ, Tsring N, Yu TY, Wu JC, Wong S, Chen GY, Dekyi P, Pan F, Xian ST, Rinchen D, Mao YQ, Zhang LF, Yao BB.

Chin J Integr Med. 2017 Dec;23(12):908-915. doi: 10.1007/s11655-016-2500-7. Epub 2016 May 4.

PMID:
27145942
6.

Chinese tuina downregulates the elevated levels of tissue plasminogen activator in sciatic nerve injured Sprague-Dawley rats.

Pan F, Yu TY, Wong S, Xian ST, Lu MQ, Wu JC, Gao YF, Li XQ, Geng N, Yao BB.

Chin J Integr Med. 2017 Aug;23(8):617-624. doi: 10.1007/s11655-015-2142-1. Epub 2015 May 13.

PMID:
25967608
7.

[Surgical treatment for displaced clavicle fracture combined with coracoid process: 9 cases report].

Yao BB, Zha L, Yin CG, Wang TL, Wang WD, Wang YB, Wu DF.

Zhongguo Gu Shang. 2014 Dec;27(12):1043-6. Chinese.

PMID:
25638896
8.

Species comparison and pharmacological characterization of human, monkey, rat, and mouse TRPA1 channels.

Bianchi BR, Zhang XF, Reilly RM, Kym PR, Yao BB, Chen J.

J Pharmacol Exp Ther. 2012 May;341(2):360-8. doi: 10.1124/jpet.111.189902. Epub 2012 Feb 7.

PMID:
22319196
9.

KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.

Zhang D, Thimmapaya R, Zhang XF, Anderson DJ, Baranowski JL, Scanio M, Perez-Medrano A, Peddi S, Wang Z, Patel JR, DeGoey DA, Gopalakrishnan M, Honore P, Yao BB, Surowy CS.

J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.

PMID:
21723881
10.

Pharmacological and molecular characterization of a dorsal root ganglion cell line expressing cannabinoid CB(1) and CB(2) receptors.

Fan Y, Hooker BA, Garrison TR, El-Kouhen OF, Idler KB, Holley-Shanks RR, Meyer MD, Yao BB.

Eur J Pharmacol. 2011 Jun 1;659(2-3):161-8. doi: 10.1016/j.ejphar.2011.03.020. Epub 2011 Mar 31.

PMID:
21458448
11.

Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.

Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, Wensink EJ, Zhan C, Carroll WA, Dart MJ, Yao BB, Honore P, Meyer MD.

Br J Pharmacol. 2011 Jan;162(2):428-40. doi: 10.1111/j.1476-5381.2010.01046.x.

12.

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.

Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD.

J Med Chem. 2010 Jan 14;53(1):295-315. doi: 10.1021/jm901214q.

PMID:
19921781
13.

In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.

Strakhova MI, Cuff CA, Manelli AM, Carr TL, Witte DG, Baranowski JL, Vortherms TA, Miller TR, Rundell L, McPherson MJ, Adair RM, Brito AA, Bettencourt BM, Yao BB, Wetter JM, Marsh KC, Liu H, Cowart MD, Brioni JD, Esbenshade TA.

Br J Pharmacol. 2009 May;157(1):44-54. doi: 10.1111/j.1476-5381.2009.00236.x.

14.

Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.

Zhu CZ, Mikusa JP, Fan Y, Hollingsworth PR, Pai M, Chandran P, Daza AV, Yao BB, Dart MJ, Meyer MD, Decker MW, Hsieh GC, Honore P.

Br J Pharmacol. 2009 Jun;157(4):645-55. doi: 10.1111/j.1476-5381.2009.00184.x. Epub 2009 Apr 3.

15.

[Retrograde interlocking intramedullary nail in treatment of humeral shaft fracture complicated with radial nerve injury].

Yao BB, Sun XM, Han B, Wang WD, Zhao FL.

Zhongguo Gu Shang. 2008 Sep;21(9):687-8. Chinese. No abstract available.

PMID:
19105285
16.

Characterization of human cannabinoid CB2 receptor coupled to chimeric Galpha(qi5) and Galpha(qo5) proteins.

Malysz J, Daza AV, Kage K, Grayson GK, Yao BB, Meyer MD, Gopalakrishnan M.

Eur J Pharmacol. 2009 Jan 28;603(1-3):12-21. doi: 10.1016/j.ejphar.2008.11.047. Epub 2008 Dec 3.

PMID:
19071106
17.

A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors.

McGaraughty S, Chu KL, Dart MJ, Yao BB, Meyer MD.

Neuroscience. 2009 Feb 18;158(4):1652-61. doi: 10.1016/j.neuroscience.2008.11.015. Epub 2008 Nov 14.

PMID:
19063946
18.

Cloning and characterization of the monkey histamine H3 receptor isoforms.

Strakhova MI, Fox GB, Carr TL, Witte DG, Vortherms TA, Manelli AM, Miller TR, Yao BB, Brioni JD, Esbenshade TA.

Eur J Pharmacol. 2008 Dec 28;601(1-3):8-15. doi: 10.1016/j.ejphar.2008.10.026. Epub 2008 Oct 21.

PMID:
18977214
19.

Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.

Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD.

J Pharmacol Exp Ther. 2009 Jan;328(1):141-51. doi: 10.1124/jpet.108.145011. Epub 2008 Oct 17.

PMID:
18931146
20.

Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.

Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Miller LN, Li L, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD.

J Med Chem. 2008 Mar 27;51(6):1904-12. doi: 10.1021/jm7011613. Epub 2008 Feb 27.

PMID:
18311894
21.

In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.

Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, Grayson GK, Zhu CZ, Pai M, Chandran P, Salyers AK, Wensink EJ, Honore P, Sullivan JP, Dart MJ, Meyer MD.

Br J Pharmacol. 2008 Jan;153(2):390-401. Epub 2007 Nov 12.

22.

Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.

Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J, Hsieh GC, Honore P, Frost JM, Dart MJ, Meyer MD, Yao BB, Cox BF, Fox GB.

Br J Pharmacol. 2008 Jan;153(2):367-79. Epub 2007 Oct 29.

23.

In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?

Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, Meyer MD.

Br J Pharmacol. 2006 Sep;149(2):145-54. Epub 2006 Aug 7.

24.

Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.

Pan JB, Yao BB, Miller TR, Kroeger PE, Bennani YL, Komater VA, Esbenshade TA, Hancock AA, Decker MW, Fox GB.

Life Sci. 2006 Aug 29;79(14):1366-79. Epub 2006 Apr 26.

PMID:
16730751
25.

Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Witte DG, Yao BB, Miller TR, Carr TL, Cassar S, Sharma R, Faghih R, Surber BW, Esbenshade TA, Hancock AA, Krueger KM.

Br J Pharmacol. 2006 Jul;148(5):657-70. Epub 2006 May 22.

26.

Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H (3) receptor isoforms.

Esbenshade TA, Krueger KM, Yao BB, Witte DG, Estvander BR, Baranowski JL, Miller TR, Hancock AA.

Inflamm Res. 2006 Apr;55 Suppl 1:S45-6. No abstract available.

PMID:
16705378
27.

Differential CNS expression and functional activity of multiple human H(3) receptor isoforms.

Esbenshade TA, Strakhova MI, Carr TL, Sharma R, Witte DG, Yao BB, Miller TR, Hancock AA.

Inflamm Res. 2006 Apr;55 Suppl 1:S38-9. No abstract available.

PMID:
16547816
28.

Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor.

Yao BB, Witte DG, Miller TR, Carr TL, Kang CH, Cassar S, Faghih R, Bennani YL, Surber BW, Hancock AA, Esbenshade TA.

Neuropharmacology. 2006 Mar;50(4):468-78. Epub 2005 Nov 28.

PMID:
16316670
29.

Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.

Esbenshade TA, Yao BB, Witte DG, Carr TL, Sharma R, Baranowski JL, Krueger KM, Miller TR, Surber BW, Faghih R, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S46-7. No abstract available.

PMID:
15928830
30.

Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.

Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. No abstract available.

PMID:
15928819
31.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.

Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. Epub 2004 Dec 17.

PMID:
15608078
32.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.

Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17.

PMID:
15608077
33.

Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.

Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S, Meyer M, Yao BB.

Eur J Pharmacol. 2004 Nov 28;505(1-3):1-9.

PMID:
15556131
34.

Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.

Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.

Biochem Pharmacol. 2004 Sep 1;68(5):933-45.

PMID:
15294456
35.

Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties.

Faghih R, Esbenshade TA, Krueger KM, Yao BB, Witte DG, Miller TM, Kang CH, Fox GB, Cowart M, Bennani YL, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S79-80. Epub 2004 Mar 5. No abstract available.

PMID:
15054629
36.

Molecular and pharmacological characterization of the monkey histamine H(3) receptor.

Yao BB, Sharma R, Cassar S, Faghih R, Bennani Y, Esbenshade TA, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S75-6. Epub 2004 Mar 5. No abstract available.

PMID:
15054627
37.

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.

Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB.

Eur J Pharmacol. 2004 Mar 8;487(1-3):183-97.

PMID:
15033391
38.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.

Gfesser GA, Zhang H, Dinges J, Fox GB, Pan JB, Esbenshade TA, Yao BB, Witte D, Miller TR, Kang CH, Krueger KM, Bennani YL, Hancock AA, Faghih R.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):673-6.

PMID:
14741266
39.

Cloning and pharmacological characterization of the monkey histamine H3 receptor.

Yao BB, Sharma R, Cassar S, Esbenshade TA, Hancock AA.

Eur J Pharmacol. 2003 Dec 15;482(1-3):49-60.

PMID:
14660004
40.

Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.

Hancock AA, Esbenshade TA, Krueger KM, Yao BB.

Life Sci. 2003 Oct 31;73(24):3043-72. Review.

PMID:
14550847
41.

D-alanine piperazine-amides: novel non-imidazole antagonists of the histamine H3 receptor.

Faghih R, Phelan K, Esbenshade TA, Miller TR, Kang CH, Krueger KM, Yao BB, Fox GB, Bennani YL, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S47-8. No abstract available.

PMID:
12755406
42.

In vitro pharmacological properties of two novel non-imidazole H3 receptor (H3R) antagonists.

Yao BB, Witte DG, Miller TR, Krueger KM, Carr TL, Kang CH, Faghih R, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S45-6. No abstract available.

PMID:
12755405
43.

Molecular modeling and pharmacological analysis of species-related histamine H(3) receptor heterogeneity.

Yao BB, Hutchins CW, Carr TL, Cassar S, Masters JN, Bennani YL, Esbenshade TA, Hancock AA.

Neuropharmacology. 2003 May;44(6):773-86.

PMID:
12681376
44.

Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.

Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):887-96. Epub 2003 Feb 20.

PMID:
12606603
45.

Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization.

Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2003 Jun;305(3):897-908. Epub 2003 Feb 20.

PMID:
12606600
46.

Direct interaction of STAT4 with the IL-12 receptor.

Yao BB, Niu P, Surowy CS, Faltynek CR.

Arch Biochem Biophys. 1999 Aug 1;368(1):147-55.

PMID:
10415122

Supplemental Content

Support Center